Sagimet Biosciences (SGMT) Cash from Financing Activities (2022 - 2025)
Sagimet Biosciences (SGMT) posted quarterly Cash from Financing Activities of $274000.0 for Q3 2025, up 1114.81% quarter-over-quarter from -$27000.0 in Q2 2024.
Sagimet Biosciences (SGMT) Cash from Financing Activities (2022 - 2025) Analysis & Trends
Sagimet Biosciences' Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $274000.0 for Q3 2025.
- In Q3 2025, Cash from Financing Activities changed N/A year-over-year to $274000.0; the TTM figure through Dec 2025 stood at $274000.0 (down 99.74% YoY), while the FY2025 annual figure was $275000.0, down 99.74% from the prior year.
- Cash from Financing Activities for Q3 2025 stood at $274000.0, up from -$27000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $104.8 million in Q1 2024, with the low at -$910000.0 in Q2 2023.
- The 4-year median for Cash from Financing Activities is -$27000.0 (2024), against an average of $27.3 million.
- Peak annual rise in Cash from Financing Activities reached 77192.65% in 2024, while the deepest fall reached 97.03% in 2024.
- Sagimet Biosciences' Cash from Financing Activities stood at -$55000.0 in 2022, then soared by 158669.09% to $87.2 million in 2023, then plunged by 100.03% to -$27000.0 in 2024, then surged by 1114.81% to $274000.0 in 2025.
- Business Quant data shows SGMT's Cash from Financing Activities at $274000.0 in Q3 2025, -$27000.0 in Q2 2024, and $104.8 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 274,000.00 |
| Sep 30, 2025 | 274,000.00 |
| Jun 30, 2024 | -27,000.00 |
| Jun 30, 2024 | -27,000.00 |
| Mar 31, 2024 | 104.85 Mn |
| Mar 31, 2024 | 104.85 Mn |
| Sep 30, 2023 | 87.21 Mn |
| Sep 30, 2023 | 87.21 Mn |
| Jun 30, 2023 | -910,000.00 |
| Jun 30, 2023 | -910,000.00 |
| Mar 31, 2023 | -136,000.00 |
| Mar 31, 2023 | -136,000.00 |
| Dec 31, 2022 | -55,000.00 |
| Dec 31, 2022 | -55,000.00 |